RxTx is Canada's authoritative source for prescribing and managing drug therapy at the point of care, providing health care professionals with online and mobile access to evidence-based, reliable Canadian drug and therapeutic information.
RxTx integrates the content from our drug and therapeutic products into one convenient resource along with other valuable external references. Our drug and therapeutic content is available in three options to suit your needs.
RxTx Subscription Options
Compare subscription options
|Features||RxTx 1||RxTx 2||RxTx 3|
|Thousands of products including Health Canada–approved drug monographs and CPhA evidence-based drgu/class monographs, Health Canada advisories and warnings linked directly to monographs.|
|Printable information for the patient handouts, written in plain language to advise patients on safe, effective use of medications.|
|Full-colour product images, accessed through drug monographs and searchable by appearance.|
|Clinical tools (e.g., drugs of choice during pregnancy and breastfeeding, drug-food interactions, lab values).|
|Printable drug monographs that allow you to select and print only the information you need.|
|Evidence-based treatment options for over 200 primary care conditions, written and peer-reviewed by expert Canadian physicians and pharmacists.|
|Easy-to-use algorithms for determining the best course of action.|
|Drug tables formatted for quick access to dose, adverse effects, drug interactions and relative costs.|
|A drug interaction analyzer to provide relevant interaction information.|
|Comparative drug costs, calculated based on therapeutic condition and length of treatment, to help prescribers weigh the economic implications of drug choices for their patients.|
|Evidence-based information covering the full spectrum of therapy on more than 140 minor ailment conditions.|
|An unrivalled compilation of nonprescription drugs and devices marketed in Canada. Products are conveniently organized into tables to highlight comparative ingredients and features.|
Each therapeutic topic from CTC and CTMA is written by an expert author and is based on the best available evidence. CPhA employs a rigorous review process to ensure that the information is accurate and unbiased. Content is extensively reviewed and validated by skilled CPhA clinical editors and by external reviewers who are recognized experts (physicians,pharmacists and nurses) in their particular clinical area.
CPhA asks authors to disclose any potential conflicts of interest. CPhA does not accept funding from pharmaceutical manufacturers for any content that we develop.